|
|
|
The BLA was submitted on August 28, 2008 for use of Menveo in subjects age 11 - 55. A Phase II study in infants published in the January 9, 2008, issue of the Journal of the American Medical Association reported that Menveo is the first meningococcal vaccine candidate to elicit a robust immune response in infants[1]. For those who survive, as many as 19% suffer serious long-term consequences such as deafness, neurological damage or limb loss.
The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "will," "can," "dedicated," "potential," or similar expressions, or by express or implied discussions regarding potential marketing approvals for Menveo or regarding potential future revenues from Menveo. Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants: A Randomized Controlled Trial. Additionally, based on its mechanism, it is believed that the compound may potentially protect against exposure to chlorine gas. A compound with the potential to protect against multiple threats would be of significant benefit in both the military and civilian efforts to protect citizens against potential threats.
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. Studies funded by the National Institutes for Health are currently underway evaluating AEOL 10150 as a treatment for exposure to mustard gas and will shortly be initiated to evaluate the compound as a treatment for exposure to chlorine gas.
l368 xanax mixing methadone and xanax xanax perfume xanax purepac photo xanax sun sensitivity
The BLA was submitted on August 28, 2008 for use of Menveo in subjects age 11 - 55.
The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "will," "can," "dedicated," "potential," or similar expressions, or by express or implied discussions regarding potential marketing approvals for Menveo or regarding potential future revenues from Menveo.htm [3.] World Health Organization. of Duke University Medical Center, was designed to test the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation. AEOL 10150 also demonstrated statistically significant reductions in markers for oxidative stress and inflammation – secondary endpoints for the study. These include:
-- Flexible Treatment Paradigm – AEOL 10150 is intended for the treatment of patients post-exposure, even in those who are already exhibiting symptoms, eliminating the need for immediate administration in a predefined treatment window.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005